Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ajulemic acid.

Jenny L Wiley1

  • 1Virginia Commonwealth University, Department of Pharmacology and Toxicology, Richmond, 23298, USA. jwiley@hsc.vcu.edu

Idrugs : the Investigational Drugs Journal
|December 2, 2005
PubMed
Summary
This summary is machine-generated.

Ajulemic acid, a novel non-steroidal anti-inflammatory drug derived from tetrahydrocannabinol, shows potential for treating pain, inflammation, and cystitis. This development offers a new therapeutic avenue for inflammatory conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.

Progress in neuro-psychopharmacology & biological psychiatry·2024
Same author

Δ<sup>9</sup>-tetrahydrocannabinol discrimination: Effects of route of administration in mice.

Drug and alcohol dependence reports·2023
Same author

Δ<sup>9</sup>-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice.

Cardiovascular toxicology·2023
Same author

Experimenter administered Δ<sup>9</sup>-THC decreases nicotine self-administration in a rat model.

Pharmacology, biochemistry, and behavior·2023
Same author

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.

Pharmacology, biochemistry, and behavior·2023
Same author

In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.

Pharmacology, biochemistry, and behavior·2022
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Drug Development
  • Inflammation Research

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • Current treatments for cystitis can have limitations.
  • Tetrahydrocannabinol (THC) derivatives are being explored for therapeutic applications.

Purpose of the Study:

  • To introduce ajulemic acid, a novel NSAID.
  • To highlight its potential in managing pain and inflammation.
  • To explore its efficacy in treating cystitis.

Main Methods:

  • Ajulemic acid is a synthetic derivative of THC.
  • It is being developed as a non-steroidal anti-inflammatory agent.
  • Preclinical studies are likely underway to assess its therapeutic profile.

Related Experiment Videos

Main Results:

  • Ajulemic acid demonstrates potential as an anti-inflammatory agent.
  • It may offer relief for pain associated with inflammatory conditions.
  • Preliminary data suggests possible benefits for cystitis treatment.

Conclusions:

  • Ajulemic acid represents a promising new therapeutic candidate.
  • Its non-steroidal, THC-derived nature offers a unique pharmacological profile.
  • Further research is warranted to establish its clinical utility for pain, inflammation, and cystitis.